for the meetings announced in this notice. The dates and times reserved for the open portions of each committee meeting are listed above.

The open public hearing portion of each meeting shall be at least 1 hour long unless public participation does not last that long. It is emphasized, however, that the 1 hour time limit for an open public hearing represents a minimum rather than a maximum time for public participation, and an open public hearing may last for whatever longer period the committee chairperson determines will facilitate the committee's work.

Public hearings are subject to FDA's guideline (subpart C of 21 CFR part 10) concerning the policy and procedures for electronic media coverage of FDA's public administrative proceedings, including hearings before public advisory committees under 21 CFR part 14. Under 21 CFR 10.205, representatives of the electronic media may be permitted, subject to certain limitations, to videotape, film, or otherwise record FDA's public administrative proceedings, including presentations by participants.

Meetings of advisory committees shall be conducted, insofar as is practical, in accordance with the agenda published in this Federal Register notice. Changes in the agenda will be announced at the beginning of the open portion of a meeting.

Any interested person who wishes to be assured of the right to make an oral presentation at the open public hearing portion of a meeting shall inform the contact person listed above, either orally or in writing, prior to the meeting. Any person attending the hearing who does not in advance of the meeting request an opportunity to speak will be allowed to make an oral presentation at the hearing's conclusion, if time permits, at the chairperson's discretion.

The agenda, the questions to be addressed by the committee, and a current list of committee members will be available at the meeting location on the day of the meeting.

Transcripts of the open portion of the meeting may be requested in writing from the Freedom of Information Office (HFI–35), Food and Drug Administration, rm. 12A–16, 5600 Fishers Lane, Rockville, MD 20857, approximately 15 working days after the meeting, at a cost of 10 cents per page. The transcript may be viewed at the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857, approximately 15 working days after the meeting, between the hours of 9 a.m. and 4 p.m., Monday through Friday. Summary minutes of the open portion of the meeting may be requested in writing from the Freedom of Information Office (address above) beginning approximately 90 days after the meeting.

This notice is issued under section 10(a)(1) and (2) of the Federal Advisory Committee Act (5 U.S.C. app. 2), and FDA's regulations (21 CFR part 14) on advisory committees.

Dated: October 12, 1995.

David A. Kessler,

Commissioner of Food and Drugs.

[FR Doc. 95–25766 Filed 10–12–95; 4:41 pm]

BILLING CODE 4160–01–P

[Docket No. 95N–0281]

''Proceedings of the 1994 Vibrio Vulnificus Workshop;'' Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of ''Proceedings of the 1994 *Vibrio vulnificus* Workshop.'' The workshop was a scientific forum that was cosponsored by FDA, the National Marine Fisheries Service (NMFS), and the Interstate Shellfish Sanitation Conference (ISSC) to: Review the current information available on the epidemiology, ecology, and pathogenicity of *Vibrio vulnificus*, as well as industry practices affecting the levels of this pathogen in seawater and shellfish, ongoing educational efforts, and other related technical information obtained since the last *Vibrio vulnificus* workshop, held in March 1988; identify further critical information needs; and identify the kind of research that will best address these needs using available government and nongovernment resources most effectively.

ADDRESSES: Submit written requests for single copies of ''Proceedings of the 1994 *Vibrio vulnificus* Workshop'' to the Program and Enforcement Branch, Office of Seafood (HFS–417), Food and Drug Administration, 200 C St. SW., Washington, DC 20204. Requests should be identified with the docket number found in brackets in the heading of this document. Send two self-addressed adhesive labels to assist that office in processing your requests. ''Proceedings of the 1994 *Vibrio vulnificus* Workshop'' is available for public examination in the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20875, between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Jeanette B. Lyon, Center for Food Safety and Applied Nutrition, Office of Seafood (HFS–417), 200 C St. SW., Washington, DC 20204, 202–418–3177.

SUPPLEMENTARY INFORMATION: *Vibrio vulnificus* is a naturally-occurring marine bacterium which has been associated with human illness and death from the consumption of raw shellfish, primarily raw oysters. Federal and State government agencies, the ISSC, academia, and the shellfish industry have been monitoring these illnesses and deaths and have focused their research efforts on the development of effective controls to prevent *Vibrio vulnificus*-related illnesses from the consumption of shellfish. In 1988, a jointly sponsored *Vibrio vulnificus* workshop was held in Washington, DC, to identify the current state of knowledge and research needs at that time.

At the 1994 workshop, experts were invited to present scientific and technical updates on the epidemiology, pathogenicity, and ecology of *Vibrio vulnificus*; the effects of time-temperature factors on outgrowth; depuration, irradiation, and other intervening control measures; and the use and effectiveness of consumer education and health advisories. In addition to the invited speakers and representatives of the sponsors, other attendees included state public health officials, industry, consumer representatives, epidemiologists, and researchers. The workshop concluded with several panel discussions during which panel members discussed their views on unresolved information and research needs and mechanisms by which these might be attained.

A draft of the proceedings was published and distributed to the participants for comment in August, 1994. The current publication incorporates their comments.

Dated: September 28, 1995.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 95–25621 Filed 10–16–95; 8:45 am]

BILLING CODE 4160–01–F

National Institutes of Health

National Cancer Institute; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Homoharringtonine as an Anticancer Agent

AGENCY: National Institutes of Health, PHS, DHHS.